Exact Mass: 340.1787
Exact Mass Matches: 340.1787
Found 281 metabolites which its exact mass value is equals to given mass value 340.1787
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
3-Hydroxyquinine
3-Hydroxyquinine is a major metabolite of quinine. The formation of 3-hydroxyquinine is catalysed by cytochrome P450 3A4. [HMDB] 3-Hydroxyquinine is a major metabolite of quinine. The formation of 3-hydroxyquinine is catalysed by cytochrome P450 3A4.
11-Hydroxytubotaiwine
11-Hydroxytubotaiwine is an alkaloid from cultured cells of Aspidosperma quebracho-blanco (quebracho). Alkaloid from cultured cells of Aspidosperma quebracho-blanco (quebracho)
19,20-(E)-Vallesamine
3-hydroxyquinidine
1-[3-(1,3-Benzodioxol-5-yloxy)propyl]-4-phenylpiperazine
Glycyl-l-histidyl-l-lysine
2,4(1H,3H)-Pyrimidinedione, 1-(cyclopropylmethyl)-6-(3,5-dimethylbenzoyl)-5-(1-methylethyl)-
Quinidine N-oxide
yohimbinic acid
relative retention time with respect to 9-anthracene Carboxylic Acid is 0.445 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.442 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.437 Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA)[1][2][3].
21-O-methylleuconolam|leuconolam methyl ether|O-methylleuconolam
Vallesamine
19,20-(E)-Vallesamine is a natural product found in Tabernaemontana citrifolia, Alstonia rostrata, and Alstonia scholaris with data available.
alpha-o-methylbotrydialone|alpha-O-methyldihydrobotrydialone
1, 2:4, 5-Di-O-cyclohexylidene-beta-D-Pyranose-Fructose
4-(Hydroxy((1S)-5-vinylquinuclidin-2-yl)methyl)-6-methoxyquinolin-2(1H)-one
11-dehydro-2,3-dinor Thromboxane B2
10-Hydroxy-16-epiaffinine
1beta,4beta-dihydroxy-8beta-acetoxy-5alphaH-eudesma-11(13)-en-12-oic acid methyl ester
5-Ac,Me ether-4,5,10-Trihydroxy-11(13)-amorphen-12-oic acid|methyl 5-acetoxy-4,5-dihydro-4,10-dihydroxy-5-acetoxyartemisinate
Yohimbic acid
Yohimbic acid is a yohimban alkaloid. It is functionally related to a 17alpha-yohimbol. C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA)[1][2][3].
[5-acetyloxy-3-(hydroxymethyl)-2-oxo-6-propan-2-ylcyclohex-3-en-1-yl] 3-methylpentanoate
[5-acetyloxy-3-(hydroxymethyl)-2-oxo-6-propan-2-ylcyclohex-3-en-1-yl] 3-methylpentanoate
Yohimbic acid
Origin: Plant; SubCategory_DNP: Monoterpenoid indole alkaloids, Yohimbinoid alkaloids, Indole alkaloids Annotation level-1 Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA)[1][2][3].
[5-acetyloxy-3-(hydroxymethyl)-2-oxo-6-propan-2-ylcyclohex-3-en-1-yl] 3-methylpentanoate [IIN-based on: CCMSLIB00000848998]
[5-acetyloxy-3-(hydroxymethyl)-2-oxo-6-propan-2-ylcyclohex-3-en-1-yl] 3-methylpentanoate [IIN-based: Match]
Ala Gly Pro Pro
Ala Pro Gly Pro
Ala Pro Pro Gly
Gly Ala Pro Pro
Gly Pro Ala Pro
Gly Pro Pro Ala
Pro Ala Gly Pro
Pro Ala Pro Gly
Pro Gly Ala Pro
Pro Gly Pro Ala
Pro Pro Ala Gly
Pro Pro Gly Ala
11-Hydroxytubotaiwine
4-(QUINOLINE-3-CARBONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
Copper Peptide
Glycyl-L-histidyl-L-lysine is a tripeptide consisting of glycine, L-histidine and L-lysine residues joined in sequence. Glycyl-L-histidyl-L-lysine is a hepatotropic immunosuppressor and shows anxiolytic effect. Glycyl-L-histidyl-L-lysine and its copper complexes show good skin tolerance[1][2][3].
1,2:5,6-DI-O-CYCLOHEXYLIDENE-3-CYANO-ALPHA-D-ALLOFURANOSE
1-[2-AMINO-1-(4-BENZYLOXY-PHENYL)-ETHYL]-PYRROLIDINE-3-CARBOXYLICACID
2-(4-(BENZYLOXY)-3-METHOXYPHENYL)-4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLANE
1,2:5,6-Di-O-cyclohexylidene-alpha-D-glucofuranose
3-[2-hydroxy-3-(propan-2-ylamino)propoxy]-2-phenyl-3H-isoindol-1-one
1,3-BIS(2,4,6-TRIMETHYLPHENYL)IMIDAZOLIUM CHLORIDE
(2S)-5-(tert-butyldiphenylsilyloxy)-1,2-epoxypentane
(2S,5R)-benzyl 5-(benzyloxyamino)piperidine -2-carboxylate
2,3:5,6-DI-O-CYCLOHEXYLIDENE-ALPHA-D-MANNOFURANOSE
(1S,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid
2,5-Ethano-2H-azocino[4,3-b]indole-6-carboxylic acid, 4-ethylidene-1,3,4,5,6,7-hexahydro-6-(hydroxymethyl)-, methyl ester
[3-carboxy-2-[(3E,5E,8E)-9-carboxynona-3,5,8-trienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(2E,5E,8E)-9-carboxynona-2,5,8-trienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(3E,5E,7E)-9-carboxynona-3,5,7-trienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(4E,6E,8E)-9-carboxynona-4,6,8-trienoyl]oxypropyl]-trimethylazanium
(E)-5-[4-hydroxy-2-[(E)-3-hydroxyoct-1-enyl]-6-oxooxan-3-yl]pent-3-enoic acid
2-methoxy-3-methyl-N-[4-(4-morpholinylmethyl)phenyl]benzamide
N-[2-(2,3-dimethylanilino)-2-oxoethyl]-3-(3-methylphenoxy)propanamide
N2-[2-(4-methylphenyl)-5-phenyl-3-pyrazolyl]benzene-1,2-diamine
4-[3-(4-Fluorophenyl)-2,5,6-trimethyl-7-pyrazolo[1,5-a]pyrimidinyl]morpholine
(2S,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2-azetidinecarbonitrile
(2S,3R,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2-azetidinecarbonitrile
(2R,3R,4R)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2-azetidinecarbonitrile
(2R,3S,4S)-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2-azetidinecarbonitrile
(1S,15R,17S,18S)-17-ethyl-7-hydroxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene-1-carboxylic acid
Gly-His-Lys
A tripeptide composed of glycine, L-histidine and L-lysine residues joined in sequence.
1-[3-(1,3-benzodioxol-5-yloxy)propyl]-4-phenylpiperazine
6-amino-2-[[2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid
AVN-101 (hydrochloride)
AVN-101 hydrochloride is a potent, brain-penetrant and orally active 5-HT7 receptor antagonist (Ki of 153 pM), with slightly lesser potency toward 5-HT6, 5-HT2A, and 5HT-2C receptors (Ki values of 2.04 nM, 1.56 ?nM, and 1.17? nM, respectively). AVN-101 hydrochloride also exhibits a rather high affinity toward histamine H1 (Ki of 0.58 nM) and adrenergic α2A, α2B, and α2C (Ki= 0.41-3.6 nM) receptors. AVN-101 hydrochloride can be studied in such diseases as general anxiety disorders, depression, schizophrenia, and multiple sclerosis[1].
GAC0003A4
GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXRβ protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies[1].
2'-(1-hydroxyethyl)-4'-methyl-9'-oxa-4'-azaspiro[indole-3,7'-tetracyclo[6.3.1.0²,⁶.0⁵,¹¹]dodecan]-2-ol
2-[(1s,12s,13r,14r,15e)-13-(hydroxymethyl)-7-methoxy-3,17-diazapentacyclo[12.3.1.0²,¹⁰.0⁴,⁹.0¹²,¹⁷]octadeca-2(10),4,6,8-tetraen-15-ylidene]ethanol
methyl (8s,13e,14s,16s,17r,18s)-13-ethylidene-8-hydroxy-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-triene-18-carboxylate
methyl (13e)-13-ethylidene-10-hydroxy-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0⁹,¹⁵]octadeca-2,4,6-triene-18-carboxylate
n-(1-hydroxy-3-phenylpropan-2-yl)-2-[(1-hydroxyethylidene)amino]-3-phenylpropanimidic acid
(7'e)-7'-ethylidene-1-methoxy-11'-oxa-5'-azaspiro[indole-3,2'-tricyclo[6.3.1.0⁴,⁹]dodecan]-2-one
15-ethylidene-6-hydroxy-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-one
12-ethyl-9-hydroxy-19-methoxy-8,16-diazatetracyclo[10.6.1.0²,⁷.0¹⁶,¹⁹]nonadeca-1(18),2,4,6,8-pentaen-17-one
methyl (4as,5r)-5-(1h-indol-2-yl)-2-methyl-1h,3h,4h,4ah,6h,8h-oxepino[4,5-c]pyridine-5-carboxylate
8-hydroxy-2-(1-hydroxyheptyl)-5-oxo-2,3,4,6,7,8-hexahydro-1-benzopyran-4-yl acetate
(1r,4s,7r,8s,9r,11s,12s)-12-hydroxy-7-methoxy-2,2,4,9-tetramethyl-5-oxo-6-oxatricyclo[6.3.1.0⁴,¹²]dodecan-11-yl acetate
n-[(2r,3r,4r,5r,7s)-5-chloro-4-ethenyl-4,8,8-trimethyl-14-azatetracyclo[7.6.1.0²,⁷.0¹³,¹⁶]hexadeca-1(15),9(16),10,12-tetraen-3-yl]methanimine
(1r,4s,7s,8s,9r,11s,12s)-12-hydroxy-7-methoxy-2,2,4,9-tetramethyl-5-oxo-6-oxatricyclo[6.3.1.0⁴,¹²]dodecan-11-yl acetate
(1's,3s,4'r,7'z,8's,9'r)-7'-ethylidene-1-methoxy-11'-oxa-5'-azaspiro[indole-3,2'-tricyclo[6.3.1.0⁴,⁹]dodecan]-2-one
19,20-(e)-vallesamine
{"Ingredient_id": "HBIN002156","Ingredient_name": "19,20-(e)-vallesamine","Alias": "19,20-(E)-vallesamine","Ingredient_formula": "C20H24N2O3","Ingredient_Smile": "CC=C1CN2CCC1C(C3=C(C2)C4=CC=CC=C4N3)(CO)C(=O)OC","Ingredient_weight": "340.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "22311;41596","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "138113964","DrugBank_id": "NA"}
19-(r)-hydroxydihydrogelsemine
{"Ingredient_id": "HBIN002214","Ingredient_name": "19-(r)-hydroxydihydrogelsemine","Alias": "NA","Ingredient_formula": "C20H24N2O3","Ingredient_Smile": "CC(C12CN(C3C1C4(C5CC2C3CO5)C6=CC=CC=C6NC4=O)C)O","Ingredient_weight": "340.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15832","TCMID_id": "9999","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101601182","DrugBank_id": "NA"}
19-(r)-hydroxydihydrokoymine
{"Ingredient_id": "HBIN002217","Ingredient_name": "19-(r)-hydroxydihydrokoymine","Alias": "NA","Ingredient_formula": "C20H24N2O3","Ingredient_Smile": "CC(C12CN(C3C1C4(C5CC2C3CO5)C6=CC=CC=C6NC4=O)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "31181","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
6,7-seco-angustilobine B
{"Ingredient_id": "HBIN012102","Ingredient_name": "6,7-seco-angustilobine B","Alias": "NA","Ingredient_formula": "C20H24N2O3","Ingredient_Smile": "CN1CCC2C(=CCOCC2(C3=CC4=CC=CC=C4N3)C(=O)OC)C1","Ingredient_weight": "340.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "41099","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "13891912","DrugBank_id": "NA"}